Cipla gets EIR from USFDA for Patalganga manufacturing facility

Cipla Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500087 | NSE: CIPLA

20 Jan 2020 Evaluate

Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for Patalganga manufacturing facility. The Company has received the EIR, indicating closure of the inspection. USFDA had conducted inspection at Patalganga manufacturing facility from November 4, 2019 to November 13, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Peers

Company Name	CMP
Sun Pharma. Inds.	1840.00
Dr. Reddys Labs.	1222.50
Cipla	1388.90
Lupin	2061.85
Zydus Lifesciences	1212.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.